Healthcare Providers Petition Myriad to Add Large Rearrangement Analysis to Standard BRACAnalysis
August 03, 2011
Healthcare Providers Petition Myriad to Add Large Rearrangement Analysis to Standard BRACAnalysis
Adding large gene rearrangement analysis to Myriad's Comprehensive BRACAnalysis test could detect variants associated with increased risk for hereditary breast and ovarian cancer that occur more frequently in some populations and would otherwise be missed.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Myriad Assures Investors of Strong Patent Position Despite ACLU Anti-Gene Patenting Lawsuit
March 10, 2010 / Pharmacogenomics Reporter - In Gene Patent Ruling, SCOTUS Draws Line Between Product of Nature and Invention
June 14, 2013 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter - GenomeWeb Feature: Regardless of Gene Patent Challenges, Myriad Faces Shifting Competitive Landscape
April 17, 2013 / Pharmacogenomics Reporter - Will Insurers Cover $700 for Myriad's Large Rearrangement Test Plus $3K for BRACAnalysis?
August 15, 2012 / Pharmacogenomics Reporter